Secondly, our study not only confirms the favorable prognosis associated with the presence of TLS in breast cancer patients but also introduces potential additional prognostic markers—CD103+ CD8+ Trm cells and NK cells within TLS. This evidence concerns the gene CD8A and Tumor Lysis Syndrome.